DB
ITOS

Dmitry Balyasny’s iTeos Therapeutics ITOS Stock Holding History

Dmitry Balyasny’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,350
Closed -$218K – 3039
2024
Q4 		$218K Buy
+28,350
New +$244K ﹤0.01% 2507

Other funds holding ITOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Dmitry Balyasny's ITOS Position: Q1 2025 in Review

Dmitry Balyasny sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 28,350 shares — an estimated $218K sold.

Dmitry Balyasny first reported a position in ITOS in Q4 2024 and held it in 1 quarter. The position peaked at $218K in Q4 2024. 132 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • Dmitry Balyasny reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 28,350 iTeos Therapeutics shares in Q1 2025, an estimated $218K.
  • Dmitry Balyasny first reported a position in iTeos Therapeutics in Q4 2024 and held it in 1 quarter.
  • Dmitry Balyasny's iTeos Therapeutics position peaked at $218K in Q4 2024.
  • 132 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.